scinai logo whitespace border (002).jpg
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023 08:23 ET | Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Molecular Diagnostic for Infectious Diseases Market Size Worth $17.61 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
October 03, 2023 09:29 ET | The Insight Partners
Pune, India, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Molecular diagnostics is referred to as the detection of genomic variants, aiming to facilitate detection, diagnosis, subclassification, prognosis, and...
Pneumagen logo.jpg
Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
October 02, 2023 04:00 ET | Pneumagen Ltd
Study achieves primary & secondary endpoints in a randomised, placebo-controlled challenge studyNeumifil delivers a statistically significant reduction in both symptomatic infection rate &...
scinai logo whitespace border (002).jpg
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
September 19, 2023 16:05 ET | Scinai Immunotherapeutics Ltd.
JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing...
Scinai Yahoo@4x300x400
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
September 13, 2023 16:13 ET | Scinai Immunotherapeutics Ltd.
Scinai’s NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis Stratum corneum regained normal appearance in laboratory 3D skin model Results from ex-vivo study...
Evaxion Logo.png
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
September 11, 2023 08:17 ET | Evaxion Biotech
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine developmentEvaxion's AI model predicts vaccine efficacy in infectious disease modelsThese results...
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
August 28, 2023 01:15 ET | Novartis Pharma AG
Sandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas  Leading global echinocandin, one of three major antifungal classes, will significantly...
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:05 ET | Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
$2.34Bn Growth for Mice Model Market Size to Hit 5.4% CAGR with CRISPR Segment Driving Growth During 2022-2028
July 25, 2023 09:19 ET | The Insight Partners
Pune, India, July 25, 2023 (GLOBE NEWSWIRE) -- According to Recently Published Report by The Insight Partners, “Mice Model Market Size Report and Forecast to 2028 - COVID-19 Impact and Global...
AMR Logo.png
Generic Drugs Market to Reach $835.7 Billion, Globally, by 2032 at 8.1% CAGR: Allied Market Research
July 20, 2023 11:36 ET | Allied Market Research
Portland, OR, July 20, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Generic Drugs Market By Therapeutic Application (Cardiovascular, Infectious Diseases, Cancer,...